Company intelligence / Profile preview

BacterioScan

St. Louis, Missouri, USA

Ownership: Private
Development stage: Other

Overview

BacterioScan 216Dx System is an FDA 510(k)-cleared IVD device utilizing laser scattering technology for rapid Urinary Tract Infection (UTI) detection and Antimicrobial Susceptibility Testing (AST) in 3 hours, boasting >97.7% sensitivity. This significantly reduces diagnosis time compared to traditional 24-30 hour methods, enabling faster antibiotic stewardship and a substantial reduction in unnecessary antibiotic prescriptions by providing rapid negative predictive value for 60-90% of UTI tests.

Therapeutic areas: Infectious Diseases
Modalities: Device
Industry: Pathology

Beyond the preview

Go deeper on BacterioScan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BacterioScan.

Explore the full profile